Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8734869 | Surgical Pathology Clinics | 2018 | 18 Pages |
Abstract
Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the breast and in the lymph nodes into a score that can be combined with other emerging prognostic factors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Veerle MD,